Pubertal Metformin Therapy to Reduce Total, Visceral, and Hepatic Adiposity - 07/03/14
, Abel Lopez-Bermejo, MD, PhD b, Marta Diaz, MD, PhD a, Maria Victoria Marcos, MD, PhD c, Francis de Zegher, MD, PhD d
Reprint requests: Lourdes Ibáñez, MD, PhD, Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Passeig de Sant Joan de Déu, 2, 08950 Esplugues, Barcelona, Spain.Abstract |
Objective |
Puberty is part of a critical window in which adiposity and its correlates can be fine-tuned toward reproduction, which implies that puberty provides an opportunity to reprogram a misprogramming that occurred in early life. We tested this hypothesis in low-birthweight (LBW) girls with precocious pubarche (PP), who are at risk for hyperinsulinemic body adiposity during and beyond puberty.
Study design |
LBW girls with PP (n = 38; mean age 8 years) were randomized to remain untreated or to receive metformin across puberty (425 mg/d for 2 years, then 850 mg/d for 2 years); subsequently, all girls were monitored for 1 year without intervention. Here we report on the latter year.
Results |
The benefits of metformin were mostly maintained during the posttreatment year so that, after 5 years, metformin therapy was associated with more lean mass; with less total, visceral, and hepatic fat; with lower circulating levels of androgens and leptin; and with elevated levels of high-molecular-weight adiponectin and undercarboxylated osteocalcin.
Conclusion |
In LBW girls with PP, pubertal metformin therapy was followed by a favorable adipokine profile and by a reduction of total, visceral, and hepatic adiposity beyond puberty.
Le texte complet de cet article est disponible en PDF.Mots-clés : AI, DHEAS, HMW, IGF-1, IHLC, LBW, MRI, PP, SHBG
Plan
| L.I., M.D., and M.V.M. are Clinical Investigators of CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain). A.L.B. is an Investigator of the Fund for Scientific Research I3 (Ministry of Education and Science, Spain). F.dZ. is a Clinical Investigator of the Fund for Scientific Research (Flanders, Belgium). |
|
| The authors declare no conflicts of interest. |
Vol 156 - N° 1
P. 98 - janvier 2010 Retour au numéro
Article précédent
- Child Mental Health Problems and Obesity in Early Adulthood
- Cristiane S. Duarte, André Sourander, Georgios Nikolakaros, Harri Pihlajamaki, Hans Helenius, Jorma Piha, Kirsti Kumpulainen, Irma Moilanen, Tuula Tamminen, Fredrik Almqvist, Aviva Must
- Baseline BMI is a Strong Predictor of Nadir BMI after Adolescent Gastric Bypass
- Thomas H. Inge, Todd M. Jenkins, Meg Zeller, Lawrence Dolan, Stephen R. Daniels, Victor F. Garcia, Mary L. Brandt, Judy Bean, Kimberlee Gamm, Stavra A. Xanthakos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?